Similarly, miR-9 has been shown to be tumor suppressive in ovarian cancer and CLL via inhibition of NF-κB pathway but oncogenic in breast cancer via activation of β-catenin signaling [17, 26, 27]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.